Abstract
No public abstract is available from the verified source records.
Laurent Bertoletti, Céline Chapelle
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
10.1183/13993003.00879-2022 · 2023
Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data
10.1378/chest.81.2.151 · 1982
Worldwide CTEPH registry: long-term outcomes with pulmonary endarterectomy, balloon pulmonary angioplasty, and medical therapy
10.1161/circulationaha.124.068610 · 2024
Chronic thromboembolic pulmonary hypertension: role of medical therapy
10.1183/09031936.00201612 · 2013
Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH
10.1016/j.blre.2024.101240 · 2024
Indications and potential pitfalls of anticoagulants in pulmonary hypertension: would DOACs become a better option than VKAs?
10.1016/j.blre.2019.05.003 · 2019
Use of direct anticoagulants in chronic thromboembolic pulmonary hypertension: an anatomopathological study of endarterectomy material
2025
Direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension and the presence of recent thrombus during pulmonary endarterectomy
10.1002/pul2.12110 · 2022
A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension
10.1111/jth.14649 · 2020
Risk of direct oral anticoagulant bioaccumulation in patients with pulmonary hypertension
10.1159/000445122 · 2016
Bleeding under anticoagulant therapy in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: incidence and prognostic impact, data from the HEMA-HTP study
2025
Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension
10.1016/j.healun.2022.02.002 · 2022
A multicenter, single-blind, randomized, warfarin-controlled trial of edoxaban in patients with chronic thromboembolic pulmonary hypertension: KABUKI trial
10.1161/circulationaha.123.067528 · 2024
Long-term real-world effectiveness and safety of edoxaban in chronic thromboembolic pulmonary hypertension: a nationwide registry study
2026
Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial
10.1016/s0140-6736(24)02842-3 · 2025
No additional external references are available.